Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
PT Darya-Varia Laboratoria Tbk's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 124.28.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PT Darya-Varia Laboratoria Tbk's liquidation value for the
three
months ended in Jun. 2026 was Rp277,694 Mil.
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
PT Darya-Varia Laboratoria Tbk's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of liquidation value, PT Darya-Varia Laboratoria Tbk's accounts receivable are only considered to be worth 75% of book value:
PT Darya-Varia Laboratoria Tbk's liquidation value for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk Change In Receivables Related Terms
PT Darya-Varia Laboratoria Tbk Change In Receivables Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk Change In Receivables Chart
PT Darya-Varia Laboratoria Tbk Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a Change In Receivables of Rp Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PT Darya-Varia Laboratoria Tbk and its competitors.
Is PT Darya-Varia Laboratoria Tbk's Change In Receivables too high?
PT Darya-Varia Laboratoria Tbk's current Change In Receivables is Rp Mil. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's Change In Receivables compare to ZTS and UTHR?
PT Darya-Varia Laboratoria Tbk's Change In Receivables of Rp Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PT Darya-Varia Laboratoria Tbk and its competitors. PT Darya-Varia Laboratoria Tbk's current Change In Receivables is Rp Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,871.79, compared to a current price of Rp1,585.00 — trading 15.3% below its estimated fair value. The current Change In Receivables is Rp Mil. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current Change In Receivables is Rp Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,585.00 is trading 15.3% below its estimated GF Value™ of Rp1,871.79.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
Change In Receivables: Rp Mil
GF Value™: Rp1,871.79 vs. price of Rp1,585.00 (15.3% below fair value)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
73GF Score
Get the complete analysis for ISX:DVLA
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
